Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis.

Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis.
Eur J Med Chem. 2020 Oct 31;:112983
Authors: Consalvi S, Poce G, Ghelardini C, Di Cesare Mannelli L, Patrignani P, Bruno A, Anzini M, Calderone V, Martelli A, Testai L, Giordani A, Biava M
Abstract
This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.
PMID: 33168231 [PubMed - as supplied by publisher]

Source: European Journal of Medicinal Chemistry - October 31, 2020 Category: Chemistry Authors: Consalvi S, Poce G, Ghelardini C, Di Cesare Mannelli L, Patrignani P, Bruno A, Anzini M, Calderone V, Martelli A, Testai L, Giordani A, Biava M Tags: Eur J Med Chem Source Type: research